EyePoint Pharmaceuticals (EYPT) Misses Q4 EPS by 55c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. FIS
6. DUOL
7. ARM
8. SWKS
9. SPY
10. XYZ

Go back to EyePoint Pharmaceuticals (EYPT) Misses Q4 EPS by 55c

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments

March 2, 2023 7:00 AM EST

Phase 2 DAVIO 2 clinical trial in wet AMD on track with topline data anticipated by year-end 2023

Phase 2 PAVIA clinical trial in non-proliferative diabetic retinopathy (NPDR) on track with enrollment completion anticipated in 4Q 2023

Net product revenues for Full Year 2022 of $39.9 million, a 13.0% increase versus Full Year 2021 of $35.3 million

$144.6M of cash and investments at December 31, 2022 with cash runway projected into 2H 2024

 Management to host a conference call and webcast today at 8:30 a.m. ET

WATERTOWN, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- EyePoint... More